

Part 1: Identification

ESC Working Group on Cardiovascular Pharmacology and Drug Therapy (WG3):

Nucleus composition:

CHAIRMAN: Luis Miguel Ruilope, Spain

VICE-CHAIRMAN: Keld Per Kjeldsen, Denmark

PAST-CHAIRMAN: Faiez Zannad, France

SECRETARY: Maria Angeles Alonso Garcia, Spain

TREASURER: Stefan Agewall, Norway

WEB EDITOR: Atul Pathak, France

Ordinary nucleus members:

Basil Lewis. Israel

Franco Naccarella, Italy

Giuseppe Rosano, Italy

Harald Schmidt, The Netherlands

Sven Wassmann, Germany

Ex-officio nucleus members:

Dan Atar, Norway

Kurt Stoschitzky, Austria

Part 2: Activities of the WG during the year

Endorsed Meetings:

CardioVascular Clinical Trialists Forum (CVCT) 2-3 December 2011, Paris, France, 360 participants.

Cardiovascular Spring Meeting: Antiarrhythmics and anticoagulants in atrial fibrillation 26-27 May 2012, Vienna, Austria, 35 participants.

Papers & Guidelines:

1. Prevention of cardiovascular disease guided by total risk estimations - challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Zannad F, Dallongeville J, Macfadyen RJ, Ruilope LM, Wilhelmsen L, De Backer G, Graham I, Lorenz M, Mancina G, Morrow DA, Reiner Z, Koenig W. Eur J Cardiovasc Prev Rehabil. 2011 Nov 3. [Epub ahead of print].

2. Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques. Zannad F, De Backer G, Graham I, Lorenz M, Mancina G, Morrow DA, Reiner Z, Koenig W, Dallongeville J, Macfadyen RJ, Ruilope LM, Wilhelmsen L; ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Fundam Clin Pharmacol. 2012 Apr; 26(2): 163-74.

3. Ultrasound and Radiology surrogate end-points in pharmacological studies. Position paper by ESC Working Group on CardioVascular Pharmacology and Drug Therapy.

Agewall S, Degroot E, Marcos-Alberca P, Zamorano JL, Barrero AA, Badano LP, Perrone-Filardi P. *Atherosclerosis* 2012 Sep; 224(1): 12-24.

Guidelines / Consensus documents:

1. ESC Guidelines for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation. Stefan Agewall, Keld Per Kjeldsen.
2. ESC Guidelines on the management of cardiovascular diseases during pregnancy. Maria Angeles Alonso Garcia.
3. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Stefan Agewall, Luis Miguel Ruilope.
4. ESC/EAS Guidelines for the management of dyslipidaemias. Stefan Agewall, member of the Task Force. Giuseppe Rosano.
5. ESC Guidelines on cardiovascular disease prevention in clinical practice. Faiez Zannad, Luis Miguel Ruilope.
6. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Faiez Zannad.
7. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Dan Atar.
8. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Dan Atar.
9. Third universal definition of myocardial infarction. Expert consensus document. Dan Atar.

Affiliated journal:

European Heart Journal accepted to renew the affiliation of the Journal "Fundamental and Clinical Pharmacology" with the ESC and the Publications Committee in particular (continuation of affiliation in 2012). Editor Atul Pathak. Fundamental and Clinical Pharmacology is endorsed by WG3.

Sessions at ESC 2011 Congress Paris, France:

1. Are there geographical variations in outcome trials?
2. The myth of class effects
3. Controversial issues in diabetes management
4. Controversies in acute coronary syndrome
5. Autonomic nervous system and humoral regulations

Part 3: Future projects / business plan

Position Papers

1. Bleeding risk in patients with CVD and antithrombotic therapy and indications for protective therapies. Accepted as position paper by ESC. In preparation. Responsible author: Stefan Agewall. Contributing WG members: Sven Wassmann, Guisepe Rosano, Harald Schmidt, Atul Pathak, Keld Per Kjeldsen.
2. Beta-blockers in Acute Coronary Syndromes without left ventricular dysfunction. Under discussion. Responsible author: Dan Atar.
3. What is the optimum potassium concentration and how to ensure it? Under discussion. Responsible author: Keld Per Kjeldsen.

Meetings:

Sessions at ESC 2012 Congress Munich, Germany:

1. Seminars and symposia accepted: Lessons learned from negative trials
2. The class effect myth: Are all drugs in a class created equal
3. Do we really use statins adequately
4. What is optimum potassium concentration and how to obtain it.
5. Influencing sudden cardiac death by pharmacotherapy
6. Safety issues with cardiovascular drugs
7. Off target – Chemotherapeutics and the cardiovascular system
8. Cardiovascular pharmacotherapy in the elderly – can a patient be too old to receive cardiovascular drug treatment
Pharmacotherapy for CV disease in pregnancy

Ordinary nucleus meeting 26 August 2012, Munich, Germany

WG general assembly 27 August 2012, Munich, Germany

Extraordinary nucleus meeting 29-30 November 2012, Paris, France

CardioVascular Clinical Trialists Forum (CVCT) 30 November - 1 December 2012, Paris, France

Additional scientific meetings as well as a position paper meeting and ad hoc meetings are in preparation.

Other projects:

1. Active Participation with scientific sessions for the 2013 ESC Congress
2. Active Participation in ESC Clinical Guidelines production 2012-2013

3. Developing an annual ESC congress on Cardiovascular Pharmacology
4. Developing an ESC textbook on Cardiovascular Pharmacology
5. Developing an ESC journal of Cardiovascular Pharmacology